SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · Q1 FY2027 net loss $2.33M

InMed Pharmaceuticals Inc. · 8-K filed Nov 3, 2026 at 16:47 ET

At the news

BEARISHIMPACT 6/10

8-K filed Nov 3, 2026 at 16:47 ET

InMed Pharmaceuticals reported Q1 FY2027 results with a net loss of $2.33M, cash burn reducing cash to $1.09M (runway into mid-November), and shareholders' equity turning negative at -$1.20M. The company is pursuing a merger with Mentari Therapeutics (shareholder vote Nov 4) and has a Nasdaq compliance plan accepted through March 2027.

  • Net loss of $2,330,778 for Q1 FY2027 vs $1,726,899 in Q1 FY2026
  • Cash and cash equivalents fell to $1,094,488 from $2,194,413 at June 30, 2026
  • Shareholders' equity turned negative at -$1,199,396 vs $1,075,007 at June 30, 2026
  • Cash runway expected only into mid-November 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access